Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
125 hedge funds and large institutions have $514M invested in Adamas Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 47 increasing their positions, 33 reducing their positions, and 24 closing their positions.
84% more call options, than puts
Call options by funds: $4.46M | Put options by funds: $2.43M
42% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 33
1% less funds holding
Funds holding: 126 → 125 (-1)
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
24% less capital invested
Capital invested by funds: $676M → $514M (-$162M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$11.1M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$8.64M |
| 3 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$5.87M |
| 4 |
BWCA
Brenner West Capital Advisors
New York
|
+$5.25M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$5.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.6M |
| 2 |
PA
Perceptive Advisors
New York
|
-$15.5M |
| 3 |
State Street
Boston,
Massachusetts
|
-$8.33M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$7.62M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.52M |
ADMS Hedge Fund Activity: Q3 2018 in Review
125 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2018, worth a combined $514M — down 24% from $676M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ADMS and 23 opened new positions — a net loss of 1 holder — while 33 trimmed existing stakes and 47 added.
The largest buyer was Macquarie Group, adding an estimated $11.1M. The largest seller was Fidelity Investments, cutting an estimated $17.6M.
- 125 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2018, down from 126 in Q2 2018.
- Funds reported $514M of Adamas Pharmaceuticals stock for Q3 2018, down 24% quarter-over-quarter.
- 23 funds opened new Adamas Pharmaceuticals positions in Q3 2018 and 24 closed out, a net change of -1 holder.
- The largest Adamas Pharmaceuticals buyer in Q3 2018 was Macquarie Group, an estimated $11.1M added.
- The largest Adamas Pharmaceuticals seller in Q3 2018 was Fidelity Investments, an estimated $17.6M sold.
Based on aggregated 13F filings for Q3 2018.